Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.

ABSTRACT: Dendritic cells (DCs) are potent inducers of adaptive immunity and their clinical use in cancer vaccine formulations remains an area of active translational and clinical investigation. Although cancer vaccines applied as monotherapies have had a modest history of clinical success, there is great enthusiasm for novel therapeutic strategies combining DC-based cancer vaccines with agents that 'normalize' immune function in the tumor microenvironment (TME). Broadly, these combination vaccines are designed to antagonize/remove immunosuppressive networks within the TME that serve to limit the antitumor action of vaccine-induced T cells and/or to condition the TME to facilitate the recruitment and optimal function and durability of vaccine-induced T cells. Such combination regimens are expected t

SUBMITTER: Fecek RJ 

PROVIDER: S-EPMC5619021 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature